Coronary atherosclerosis leading to ischemic artery disease is one of the etiological factors to develop heart failure (HF). This study aimed to investigate potential biomarkers for discriminating HF in atherosclerotic patients. This study included 40 consecutive atherosclerotic patients who underwent angiography. Concentrations of B-type natriuretic peptide (BNP), fibronectin type III domain containing 5 (FNDC5), and Phosphodiesterase 9A (PDE9A) were measured in 20 atherosclerotic patients with HF symptoms/signs and 20 without HF symptoms/signs. Circulating BNP levels were elevated, while FNDC5 levels were reduced in atherosclerotic patients with HF symptoms/signs compared to those without HF symptoms/signs. Pearson correlation analysis showed a significant correlation between FNDC5 and BNP. Receiver Operating Characteristics analysis indicated that both FNDC5 and BNP were able to discriminate HF in atherosclerotic patients. Our findings suggest that FNDC5, along with BNP, has independent value as a biomarker for discriminating HF in patients with coronary atherosclerosis.

Graphical Abstract

中文翻译：

---

探索用于鉴别冠状动脉粥样硬化患者心力衰竭的潜在生物标志物 FNDC5

冠状动脉粥样硬化导致缺血性动脉疾病是发生心力衰竭（HF）的病因之一。本研究旨在研究区分动脉粥样硬化患者心力衰竭的潜在生物标志物。这项研究包括 40 名连续接受血管造影的动脉粥样硬化患者。在 20 名有心力衰竭症状/体征的动脉粥样硬化患者和 20 名无心力衰竭症状/体征的动脉粥样硬化患者中测量了 B 型利钠肽 (BNP)、纤连蛋白 III 型结构域 5 (FNDC5) 和磷酸二酯酶 9A (PDE9A) 的浓度。与没有心力衰竭症状/体征的动脉粥样硬化患者相比，有心力衰竭症状/体征的动脉粥样硬化患者的循环 BNP 水平升高，而 FNDC5 水平降低。 Pearson相关分析显示FNDC5与BNP之间存在显着相关性。受试者操作特征分析表明，FNDC5 和 BNP 都能够区分动脉粥样硬化患者的心力衰竭。我们的研究结果表明，FNDC5 与 BNP 一起作为区分冠状动脉粥样硬化患者心力衰竭的生物标志物具有独立价值。

图形概要